Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer

Kathy D. Miller, Judy Sisk, Rafat Ansari, Gary Gize, Sreenivasa Nattam, Kenneth Pennington, Frank Monaco, George W. Sledge

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing metastatic breast cancer. To date, 27 patients have received paclitaxel at 175 mg/m2 over 3 hours on day 1, plus gemcitabine at 1,200 mg/m2 on days 1 and 8, plus trastuzumab at a 4-mg/kg loading dose on day 1, followed by 2 mg/kg weekly. Treatment cycles were repeated every 21 days. Responding or stable patients who had received six cycles of combination therapy continued single-agent trastuzumab weekly until disease progression. Treatment was generally well tolerated with grade 4 toxicity limited to myelo-suppression. In all, 12 patients have achieved a partial remission and I patient had progressive disease; 14 patients continue treatment and have not yet been evaluated for response. Combination treatment with paclitaxel, gemcitabine, and trastuzumab is well tolerated and appears to be highly active. Accrual will continue to a total enrollment of 46 patients.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalONCOLOGY
Volume15
Issue number2 SUPPL. 3
StatePublished - 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Miller, K. D., Sisk, J., Ansari, R., Gize, G., Nattam, S., Pennington, K., Monaco, F., & Sledge, G. W. (2001). Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. ONCOLOGY, 15(2 SUPPL. 3), 38-40.